NovoCure Ltd. Release: NCCN Guidelines Recommend Tumor Treating Fields As A Standard Treatment Option For Recurrent Glioblastoma

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure, a commercial stage oncology company, announced today that Optune has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN GuidelinesĀ®) for Central Nervous System Cancers. The updated NCCN Guidelines indicate that physicians should consider alternating electric field therapy, or Tumor Treating Fields (TTFields), for patients with glioblastoma (GBM) brain tumors that recur or progress after initial treatment. Optune has been upgraded from a Category 3 to a Category 2B treatment, reflecting that there is NCCN consensus that the intervention is appropriate.

Help employers find you! Check out all the jobs and post your resume.

Back to news